Triasima Portfolio Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-5,693
Closed -$490K 159
2024
Q4
$490K Sell
5,693
-27,281
-83% -$2.95M 0.1% 118
2024
Q3
$3.93M Sell
32,974
-29,798
-47% -$3.97M 0.88% 40
2024
Q2
$8.96M Sell
62,772
-69
-0.1% -$9.14K 0.82% 31
2024
Q1
$8.07M Sell
62,841
-3,427
-5% -$408K 0.68% 34
2023
Q4
$6.86M Sell
66,268
-2,176
-3% -$215K 0.57% 36
2023
Q3
$6.22M Sell
68,444
-908
-1% -$80K 0.57% 35
2023
Q2
$7.43M Sell
69,352
-3,152
-4% -$257K 0.47% 43
2023
Q1
$5.77M Buy
72,504
+3,316
+5% +$235K 0.48% 39
2022
Q4
$4.68M Sell
69,188
-4,898
-7% -$287K 0.36% 51
2022
Q3
$3.69M Sell
74,086
-27,770
-27% -$1.49M 0.3% 52
2022
Q2
$5.67M Sell
101,856
-2,160
-2% -$120K 0.4% 40
2022
Q1
$5.78M Sell
104,016
-3,060
-3% -$157K 0.28% 45
2021
Q4
$6M Buy
107,076
+7,980
+8% +$432K 0.29% 45
2021
Q3
$4.76M Buy
99,096
+21,316
+27% +$1.03M 0.25% 50
2021
Q2
$3.26M Buy
77,780
+35,200
+83% +$1.36M 0.16% 61
2021
Q1
$1.44M Buy
42,580
+15,000
+54% +$534K 0.07% 109
2020
Q4
$963K Buy
+27,580
New +$953K 0.05% 111

Other funds holding NVO

Triasima Portfolio Management's NVO Position: Q1 2025 in Review

Triasima Portfolio Management sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 5,693 shares — an estimated $490K sold.

Triasima Portfolio Management first reported a position in NVO in Q4 2020 and held it in 17 quarters. The position peaked at $8.96M in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Triasima Portfolio Management reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Triasima Portfolio Management sold 5,693 Novo Nordisk shares in Q1 2025, an estimated $490K.
  • Triasima Portfolio Management first reported a position in Novo Nordisk in Q4 2020 and held it in 17 quarters.
  • Triasima Portfolio Management's Novo Nordisk position peaked at $8.96M in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Triasima Portfolio Management's 13F filing for Q1 2025, filed 2 May 2025.